title: Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.
abstract: OBJECTIVE
  To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), an extended-release injectable suspension of aripiprazole, in obese and nonobese patients.
  
  
  METHODS
  This post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study (NCT00706654) compared the clinical profile of AOM 400 in obese (body mass index [BMI] ≥30 kg/m(2)) and nonobese (BMI <30 kg/m(2)) patients with schizophrenia for ≥3 years. Patients were randomized 2:2:1 to AOM 400, oral aripiprazole 10-30 mg/d, or aripiprazole once-monthly 50 mg (AOM 50 mg) (subtherapeutic dose). Within obese and nonobese patient subgroups, treatment-group differences in Kaplan-Meier estimated relapse rates at week 26 (z-test) and in observed rates of impending relapse through week 38 (chi-square test) were analyzed. Treatment-emergent adverse events (TEAEs) (>10% in any treatment group) were summarized.
  
  
  RESULTS
  At baseline of the randomized phase, obesity rates were similar among patients randomized to AOM 400 (n=95/265, 36%), oral aripiprazole (n=95/266, 36%), and AOM 50 mg (n=43/131, 33%). In both obese and nonobese patients, relapse rates through week 38 for patients randomized to AOM 400 (obese, 7.4%; nonobese, 8.8%) were similar to those in patients on oral aripiprazole (obese, 8.4%; nonobese, 7.6%), whereas relapse rates were significantly lower with AOM 400 versus AOM 50 mg (obese, 27.9% [P=0.0012]; nonobese, 19.3% [P=0.0153]). The most common TEAEs with AOM 400 in obese and nonobese patients were insomnia (12.6% and 11.2%), headache (12.6% and 8.2%), injection site pain (11.6% and 5.3%), akathisia (10.5% and 10.6%), upper respiratory tract infection (10.5% and 4.7%), weight increase (10.5% and 8.2%), and weight decrease (6.3% and 11.8%). Within the AOM 400 group, 7.6% of patients who were nonobese at baseline became obese, and 17.9% of obese patients became nonobese during randomized treatment.
  
  
  CONCLUSIONS
  The clinical profile of AOM 400 was similar in obese and nonobese patients.
authors.affiliation: Department of Neurosciences, KU Leuven, Belgium.
authors.forename: Marc
authors.initials: M
authors.lastname: De Hert
authors.affiliation: Lundbeck LLC, Deerfield, IL, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Eramo
authors.affiliation: Otsuka Pharmaceutical Europe Ltd., Wexham, UK.
authors.forename: Wally
authors.initials: W
authors.lastname: Landsberg
authors.affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
authors.forename: Dusan
authors.initials: D
authors.lastname: Kostic
authors.affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
authors.forename: Lan-Feng
authors.initials: LF
authors.lastname: Tsai
authors.affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
authors.forename: Ross A
authors.initials: RA
authors.lastname: Baker
keywords: antipsychotic; aripiprazole once-monthly; long-acting injectable; obesity; schizophrenia